View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 13, 2020updated 12 Jul 2022 11:48am

Glenmark begins Phase III trials of favipiravir for Covid-19 in India

India-based Glenmark Pharmaceuticals has started Phase III clinical trials of anti-flu drug favipiravir as a potential treatment for patients suffering from Covid-19 in the country.

India-based Glenmark Pharmaceuticals has started Phase III clinical trials of anti-flu drug favipiravir as a potential treatment for patients suffering from Covid-19 in the country.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The company, which is the first in India to conduct Phase III trials of the drug for Covid-19, secured approval from the Drug Controller General of India (DCGI).

Favipiravir is a generic version of Fujifilm Toyama Chemical’s influenza drug Avigan, which showed activity against influenza viruses and holds approval in Japan for treating new influenza virus infections.

Glenmark developed the drug’s API and formulations internally. If commercialised in India, the drug will be available under the brand name ‘FabiFlu’.

Glenmark Pharmaceuticals India Formulations, Middle East and Africa president Sujesh Vasudevan said: “Our effort is to launch a treatment for COVID-19 patients as soon as possible and control the spread of the pandemic.

“We will do all it takes to ensure accessibility of the product across the country if the clinical trials are successful.”

According to the approved study protocol, the Phase III trial will enrol 150 patients with mild to moderate Covid-19. More than ten government and private hospitals in India are being recruited for the trial.

Participants will be given favipiravir plus standard supportive care or standard supportive care alone. Treatment duration of the study is a maximum of 14 days and the total duration will be a maximum of 28 days from randomisation.

Glenmark Pharmaceuticals Global Specialty/Branded Portfolio clinical development vice-president and head Dr Monika Tandon said: “We believe the study results will be significant as there is currently no effective treatment for the virus.

“The data we get from these trials will point us in a clearer direction with regard to Covid-19 treatment and management.”

The company expects the study to be completed by July or August this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena